VIABILITY AND INFECTIVITY OF CRYOPRESERVED PLASMODIUM VIVAX SPORozoites

Rapatbhorn Patrapuvich, Kaewta Lerdpanyangam, Rachaneeporn Jenwithisuk, Siriwan Rungin, Rachasak Boonhok, Apisak Duangmanee, Narathatai Yimamnuaychok and Jetsumon Sattabongkot

Mahidol Vivax Research Unit (MVRU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Abstract. Plasmodium vivax presents a great challenge to malaria control because of the ability of its dormant form in the liver, the hypnozoite, to cause relapse in otherwise fully recovered patient. Research efforts to better understand P. vivax hypnozoite biology have been hampered by the limited availability of its sporozoite form responsible for liver infection. Thus, the ability to cryopreserve and recover P. vivax sporozoites is an essential procedure. In this study, protective effects of hydroxyethyl starch (HES) alone and in combination with other cryoprotectants on P. vivax sporozoite recovery, viability and in vitro infectivity of a human liver HC-04 cell line were investigated. Sporozoites were harvested from P. vivax-infected female Anopheles mosquitoes and cryopreserved at a freezing rate of -1°C/minute to a final temperature of -80°C before being stored in a vapor phase liquid nitrogen tank. Cryopreserved sporozoites were thawed at 37°C and recovery of intact sporozoites assessed using a hemocytometer. Sporozoite viability and in vitro infectivity was measured using a gliding and an indirect immunofluorescence assay, respectively. A combination of 10% HES + 50% fetal bovine serum was the best cryopreservant compared to HES solution alone or mixed with cryopreservants such as dimethyl sulfoxide (DMSO) and sucrose. A mixture of bovine serum albumin, DMSO and sucrose in RPMI 1640 medium constituted an alternative cryopreservant. Sporozoites recovered from all cryopreservation media exhibited motility and infectivity of < 0.1% and < 0.001%, respectively. Thus, there is an urgent need for a vast improvement in cryopreservation procedures of viable and infective P. vivax sporozoites necessary for advancing research on hypnozoite biology.

Keywords: Plasmodium vivax, cryopreservation, malaria, sporozoite

Correspondence: Dr Rapatbhorn Patrapuvich, Mahidol Vivax Research Unit (MVRU), Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand.
Tel: +66 (0) 2354 9100-4 ext 2020; Fax: +66 (0) 2354 8051
E-mail: rapatbhorn.pat@mahidol.edu

INTRODUCTION

Malaria is caused by infection with Plasmodium parasites, which are transmitted to humans through the bites of infected female Anopheles mosquitoes. Malaria parasites in the form of sporozoites injected from mosquito salivary...
glands into the host blood stream and, upon reaching the liver, sporozoites traverse liver sinusoidal barrier including liver-resident macrophages (Kupffer cells) and migrate through a number of hepatocytes before finally invading hepatocytes, in which they undergo intra-cellular differentiation and multiplication (Lindner et al., 2012). After 6-8 days of development in the liver, tens of thousands of merozoite forms are released into the blood stream ready to red blood cells and initiate the blood stage cycle of infection, which is associated with the clinical symptoms of malaria disease.

Of the five *Plasmodium* species that infect humans, *P. vivax* is the most prevalent with almost half of the world’s population at risk (WHO, 2014). Although *P. vivax* infection results in mild clinical symptoms, severe outcomes have been reported and are becoming more increasingly detected (Price et al., 2009). In addition, *P. vivax* has an ability to remain dormant in the liver, known as hypnozoites, which can cause infections (relapses) weeks, months or even years after the primary infection (Wells et al., 2010). To date, primaquine is the only approved drug that effectively eliminates hypnozoites, but there is a risk of severe hemolytic toxicity in individuals with glucose-6-phosphate dehydrogenase (G6PD)-deficiency and reports of primaquine tolerance in patients have compromised its clinical use (Chiang et al., 2012; Townell et al., 2012; Bright et al., 2013).

An alternative drug, targeting *P. vivax* hypnozoites, tafenoquine, is currently in Phase III clinical trials, but the possibility of hemolytic crisis in G6PD-deficient patients, although low, has to be taken into consideration (Campo et al., 2015). Thus, there still is a need to develop safer drugs to eradicate liver-stage *P. vivax*.

A major obstacle to achieving the objective of *P. vivax* control and ultimately complete elimination is the limited knowledge of hypnozoite biology. This is due in part to the lack of a reliable method for *in vitro* culture of liver stage parasites, although new culture techniques have recently been reported (March et al., 2013; Maher et al., 2014; Patrapuvich et al., 2015). However, access to *P. vivax* sporozoites remains a major bottleneck to advances in research on hypnozoites, both in the area of drug discovery and vaccine development. In order to obtain *P. vivax* sporozoites, female *Anopheles* mosquitoes have to be fed on blood obtained from *P. vivax*-infected patients through an artificial membrane-feeding device (Sattabongkot et al., 2003). In addition, creating of a reliable source of sporozoites requires a well-established insectary at field sites (Campo et al., 2015). The main disadvantages of these methods are a reduction in parasite viability during transportation of infected mosquitoes to the laboratory and the logistical and regulatory challenges. Continuous *in vitro* culture of blood stage *P. vivax* has yet to be established as a feasible alternative to *in vivo* infected blood (Roobsoong et al., 2015).

Cryopreservation offers another strategy to overcome limitations in obtaining access to *P. vivax* sporozoites. Retention of sporozoite viability after a year of cryopreservation in plasma or serum was reported (Jeffery and Rendtorff, 1955). Other effective cryopreservants include a combination of serum and hydroxylethyl starch (HES) (Leef et al., 1979; Hollingdale et al., 1985) and bovine serum albumin (Lamke and Liljedahl, 1976).

The present study demonstrates the utilization of HES in cryopreservation of *P. vivax* sporozoites. In addition, recovery of sporozoite following freezing, viability and *in vitro* infectivity of human hepatocyte HC-04 cells were examined.
MATERIALS AND METHODS

Collection of P. vivax-infected Anopheles mosquitoes

Blood samples were collected from P. vivax-infected individuals in Kan-chanaburi and Tak Provinces, Thailand. Laboratory-reared female Anopheles dirus were membrane-fed with patients’ blood samples and subsequently kept at 26°C and 75% humidity with access to cotton wool soaked in 10% sucrose solution (Sat-tabongkot et al., 2003). Mosquito infection was monitored at day 7 post-feeding for midgut oocysts using a mercurochrome staining method (Usui et al., 2011). Salivary gland sporozoites were examined on day 14 post-feeding.

Experimental protocols were approved by the Ethical Review Committee, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (human use protocol TMEC 11-033). Written approval consents were obtained prior to blood collection. Infected subjects were treated with radical curative regimen of chloroquine and primaquine according to WHO guideline (WHO, 2015).

Salivary gland sporozoites

Salivary gland sporozoites were dissected from anesthetized infected mosquitoes using a standard protocol (Kennedy et al., 2012). In brief, salivary glands of 50 mosquitoes infected for 4-22 days were dissected and placed in 50 µl of either ice-cold RPMI 1640 medium (Gibco, Gaitherberg, MD), Schneider’s Drosophila medium (Gibco) or Grace’s insect medium (Gibco), and ground with a sterile pestle. Released sporozoites were counted in a hemocytometer and kept on ice until used.

Cryopreservation of P. vivax sporozoites

A suspension of 1x10^6 P. vivax sporozoites was sedimented in a cryo-vial at 13,500g for 10 minutes at 4°C, re-suspended in 100 µl of freshly prepared freezing media (Table 1) at a concentration of 10^4 sporozoites/µl and frozen at a rate of -1°C/minute to -80°C in a controlled-rate freezer (Thermo Scientific Nalgene, Rockford, IL). After storage at -80°C for 24 hours, samples were transferred and stored in the vapor phase of liquid nitrogen.

Thawing of P. vivax sporozoites

Frozen P. vivax sporozoites were thawed by shaking in a water bath at 37°C for 30 seconds and the sporozoite suspensions were mixed with 500 µl of complete medium [1:1 MEM:Ham’s F12 media supplemented with 10% heat inactivated fetal bovine serum (FBS) (Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin], then sedimented at 13,500g for 10 minutes at room temperature. Sporozoites were re-suspended in 200 µl of complete medium. Recovery of intact sporozoites was determined by counting in a hemocytometer and recorded as percent cryopreserved parasites.

Gliding motility assay

Gliding motility assay was performed as previously described (Lupton et al., 2015). In short, glass cover slips coated with 10 µg/ml of anti-P. vivax circumsporozoite surface protein antibodies (anti-PvCSP) (kindly provided by RA Wirtz, CDC, USA) in phosphate-buffered saline (PBS) were placed in wells of a 24-well plate (Jet Bio-Filtration, Guangzhou, China) and sporozoite suspension (3x10^4 in complete medium) was introduced into the well. The plate was centrifuged at 1,500g for 5 minutes at room temperature and incubated at 37°C for 30 minutes. The glass cover slips were treated with 4% paraformaldehyde for 20 minutes at room temperature followed by 1% BSA.
solution for 15 minutes at room temperature. Then cover slips were treated with 10 µg/ml mouse primary anti-PvCSP in 1% BSA solution, followed by goat secondary Alexa Fluor® 488-conjugated anti-mouse IgG antibodies (1:500 dilution; Invitrogen, Carlsbad, CA). Sporozoite CSP gliding trails on the cover slips were visualized under a fluorescent microscope (ZEISS AXIO Scope.A1, Jena, Germany). As control, pre-frozen sporozoite gliding motility was determined by counting the numbers of sporozoites that completed at least one circle per 300 sporozoites. Gliding motility of thawed cryopreserved sporozoites was determined by counting sporozoites that have gliding trails per total sporozoites on entire coverslip.

**Sporozoite infectivity assay**

Human hepatocyte HC-04 cells (3x10⁵) grown in complete medium in an 8-well Lab-Tek II plate (Nalgene Nunc International, Naperville, IL) at 37°C for 18-20 hours were used for sporozoite infectivity assay as previously described (Sattabongkot *et al*, 2006). Medium was removed by aspiration and 3x10⁵ pre-cryopreserved or 3-7.4 x10⁵ thawed sporozoites in 150 µl of infection medium (1:1 MEM:Ham’s F12 media supplemented with 10% heat inactivated FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B) were added to HC-04 cells. After 4 hours of incubation at 37°C, uninvasion sporozoites were removed by aspiration, then 400 µl aliquot of fresh infection medium was added and the cell culture was maintained at 37°C for 4 days with daily change of medium prior to visualization of the liver stage parasites (EEs) by indirect immunofluorescence assay (IFA). Cells were washed three times with PBS, incubated with 4% paraormaldehyde for 20 minutes and permeabilized by treating with 0.1% Triton X-100. Cells then were added with 3% BSA solution, followed by mouse anti-PbHsp70 antibodies (clone 4C9) (Tsuji *et al*, 1994), then goat secondary IgG Alexa Fluor® 488-conjugated anti-mouse antibodies (1:500 dilu-

---

### Table 1

Recipe for preparation of cryopreservant media.

<table>
<thead>
<tr>
<th>Reagent</th>
<th>HES</th>
<th>10% HES</th>
<th>HES + 10% DMSO</th>
<th>HES + 10% DMSO + 250 mM sucrose</th>
<th>RPMI + 0.5% BSA + 10% DMSO + 250 mM sucrose</th>
</tr>
</thead>
<tbody>
<tr>
<td>HESTAR-200™ 6% (Clarins Lifesciences, India)</td>
<td>1 ml</td>
<td>0.1 ml</td>
<td>0.9 ml</td>
<td>0.8 ml</td>
<td>-</td>
</tr>
<tr>
<td>FBS</td>
<td>-</td>
<td>0.5 ml</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MEM/Ham’s F12</td>
<td>-</td>
<td>0.4 ml</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DMSO</td>
<td>-</td>
<td>-</td>
<td>0.1 ml</td>
<td>0.1 ml</td>
<td>0.1 ml</td>
</tr>
<tr>
<td>2.5 M sucrose</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.1 ml</td>
<td>0.1 ml</td>
</tr>
<tr>
<td>RPMI 1640</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.1 ml</td>
<td>0.7 ml</td>
</tr>
<tr>
<td>5% BSA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0.1 ml</td>
</tr>
</tbody>
</table>

BSA, bovine serum albumin; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; HES, hydroxyethyl starch.
Cryopreserved *Plasmodium vivax* sporozoites

Vol 47  No. 2  March 2016

**Fig 1—*P. vivax* sporozoite production.** *P. vivax* sporozoites were dissected from *An. dirus* mosquitoes membrane-fed on 115 patients’ blood samples collected at Tak and Kanchanaburi Provinces, Thailand during 2012-2014.

**Statistical analysis**

At least three independent experiments were conducted in duplicate and results expressed as mean ± SEM. Difference of the data was determined using standard Student’s *t*-test and statistical significance is accepted when a *p*-value is < 0.05.

**RESULTS**

**Supply of *P. vivax* sporozoites**

Owing to the lack of *P. vivax in vitro* blood stage culture, sporozoite supply has to rely on mosquito feeding of *P. vivax*-infected patients’ blood. The numbers of salivary gland sporozoites from infected mosquitoes varied with different batches of patients’ blood samples. Among 115 *P. vivax* cases collected during 2012 to 2014, 50% had infection rates resulting in production of > 50,000 salivary gland sporozoites per mosquito (Fig 1). In order to reduce mosquito debris and microbial contaminants during salivary gland dissection, only mosquitoes with ≥ 50,000 sporozoites were chosen for further study.

**P. vivax** sporozoite collecting media

Ideally, a medium used for collecting sporozoites harvested from infected mosquito salivary glands should contain components that retain both viability and infectivity of the sporozoites. A comparison of human hepatocyte HC-04 cell infectivity of fleshly isolated sporozoites collected in RPMI 1640 and two insect media, Schneider’s and Grace’s, in the absence of added serum albumin so as not to cause sporozoite activation before reaching the hepatocyte cells (Vanderberg, 1974),
Table 2

Gliding motility and *in vitro* infectivity of *P. vivax* sporozoites following cryopreservation and thawing compared to freshly prepared sporozoites from mosquito salivary glands.

<table>
<thead>
<tr>
<th>Medium</th>
<th>Number added&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Before cryopreservation</th>
<th>Number added&lt;sup&gt;a&lt;/sup&gt;</th>
<th>After cryopreservation and thawing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Gliding (%)</td>
<td>Number invaded</td>
<td>Infectivity (%)</td>
</tr>
<tr>
<td>HES</td>
<td>300,000</td>
<td>29</td>
<td>153</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>37</td>
<td>182</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>69</td>
<td>34</td>
<td>0.01</td>
</tr>
<tr>
<td>10% HES + 50% FBS</td>
<td>300,000</td>
<td>29</td>
<td>153</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>37</td>
<td>182</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>69</td>
<td>34</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>90</td>
<td>124</td>
<td>0.04</td>
</tr>
<tr>
<td>RPMI + 10% DMSO +250 mM sucrose + 0.5% BSA</td>
<td>300,000</td>
<td>29</td>
<td>153</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>37</td>
<td>182</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>23</td>
<td>66</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>300,000</td>
<td>90</td>
<td>124</td>
<td>0.04</td>
</tr>
</tbody>
</table>

<sup>a</sup>Total number of frozen sporozoites recovered from cryopreservation and added to HC-04 cell culture for infectivity assay. Data are mean values from each experiment conducted in duplicate. BSA, bovine serum albumin; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; HES, hydroxylethyl starch.
Fig 2 – Gliding motility of freshly prepared and cryopreserved *P. vivax* sporozoites. Tracks of motile sporozoites on glass coverslips coated with 10 µg/ml anti-PvCSP were visualized under a fluorescent microscope (ZEISS AXIO Scope.A1) following treating with 10 µg/ml mouse primary anti-PvCSP antibodies and goat secondary IgG Alexa Fluor® 488-conjugated anti-mouse antibodies (1:500 dilution; Invitrogen). Representative images are shown for (A) freshly prepared sporozoites and sporozoites cryopreserved in (B) hydroxylethyl starch (HES) solution, (C) 10% HES + 50% fetal bovine serum and (D) RPMI 1640 medium + 0.5% bovine serum albumin + 10% dimethyl sulfoxide + 250 mM sucrose. CSP, circumsporozoite surface protein.

Fig 3 – *In vitro* growth of intra-hepatocytic *P. vivax* in human hepatocyte HC-04 cells. Freshly prepared (A), cryopreserved in hydroxylethyl starch (HES) solution (B) and cryopreserved in 10% HES + 50% fetal bovine serum (C) sporozoites were co-cultured for 4 days with HC-04 cells and intra-cellular parasites visualized by indirect immunofluorescence assay using antibodies against parasite HSP-70 (green). Red = Alexa Fluor 568 phalloidin-labelled hepatocyte F-actin, blue = DAPI-labelled hepatocyte nucleus. Bar = 10 µm.

Following 4 days of co-culture showed using IFA that sporozoites maintained in RPMI 1640 medium are significantly more infective (0.044 ± 0.004%) than those in Schneider’s (0.012 ± 0.004%) or Grace’s medium (0.014 ± 0.006%) (p = 0.005 and 0.016, respectively).

**Recovery of intact *P. vivax* sporozoites after cryopreservation**

When HES alone was used for cryopreservation of *P. vivax* sporozoites,
Viability and infectivity of cryopreserved *P. vivax* sporozoites

Viability of *P. vivax* sporozoites was measured in terms of their gliding motility, which in freshly prepared *P. vivax* sporozoites ranged from 29% to 90%, but dropped drastically following cryopreservation (0.05 ± 0.03%), with optimum viability being achieved with a mixture of 10% HES + 50% FBS (Table 2). Fig 2 shows typical gliding trails for freshly prepared and thawed sporozoites.

**In vitro** infectivity of HC-04 cells by cryopreserved sporozoites was only ≤5% of freshly prepared samples (Table 2). Smaller EE forms were obtained from cryopreserved compared with freshly prepared sporozoites, indicative of slower/retarded growth (Fig 3). No correlation between freshly isolated *P. vivax* sporozoite viability and infectivity of HC-04 cells was observed (Fig 4).

**DISCUSSION**

The availability of *P. vivax* sporozoites only from mosquitoes fed on blood from infected subjects has severely hampered drug discovery and vaccine development of pre-erythrocytic stages of this highly prevalent parasite. Considerable amounts of *P. vivax* sporozoites (≥ 50,000 per mosquito) have been acquired through artificial membrane feeding technique (Sattabongkot *et al.*, 2003). As transportation of infected mosquitoes among laboratories in not a feasible undertaking and *P. vivax* sporozoite viability rapidly decreases once removed from mosquito salivary...
glands (Beier, 1998). One resource is shipment of cryopreserved *P. vivax* sporozoites freshly dissected from mosquitoes.

Although a suitable solution was found to maintain viable *P. vivax* sporozoites following their removal from mosquitoes, disappointing recoveries of both viability and infectivity of a human hepatocyte cell line were obtained despite the use of a variety of cryopreservant solutions. Those few hardy *P. vivax* sporozoites that managed to invade and develop in hepatocytes into merozoites, albeit at a slower rate than freshly prepared samples. Taking into account this *caveat*, the procedure may suffice for *in situ* studies of liver stage *P. vivax* obtained from cryopreserved sporozoites.

Similar results were reported for rodent sporozoites using HES as a cryoprotective agent (Hollingdale *et al.*, 1985). A comparison of infectivity of freshly prepared and commercially available cryopreserved *P. vivax* sporozoites in a micro patterned co-culture liver stage model showed approximately 90% loss in infectivity of the latter sporozoites (March *et al.*, 2013). Until a better cryopreservation technique is developed, the only other alternative is to increase the numbers of sporozoites to be frozen in each batch.

A relationship between gliding motility and infectivity of sporozoites has been reported (Vanderberg, 1974, 1975). However, this was not borne out in this study. It is recommended to carry out both assays on each batch of *P. vivax* sporozoites rather than depend on viability (gliding motility) assay alone.

In conclusion, cryopreserved *P. vivax* sporozoites are the only means for supporting liver-stage malaria research community when access to sporozoite-infected mosquitoes is not readily available. However, the extremely low viability and liver infectivity of cryopreserved *P. vivax* sporozoites constitute a very serious impediment and the situation provides an opportunity for a more concerted effort on the part of *P. vivax* research community to help hurdle this stumbling block, particularly as regards development of better cryopreservation technologies and improvement in efficiency of *P. vivax* sporozoite liver infectivity and intra-hepatocyte development.

*Addendum:* While this manuscript was in preparation, Singh *et al.* (2015) reported similar results on the viability of *P. vivax* sporozoites cryopreserved in RPMI 1640 medium.

**ACKNOWLEDGEMENTS**

This study was supported in part by the Bill and Melinda Gates Foundation, Congressionally Directed Medical Research Program (to JS), US DoD (to JS), and an ICTM grant, Faculty of Tropical Medicine, Mahidol University (to RP). The authors thank Phongthon Kanjanasiriirat for technical assistance, Nattapat Rochanarutaiprid for assistance in the insectary and mosquito dissection, and Kajohnkiart Janebodin for assistance in the manuscript preparation.

**REFERENCES**


Usui M, Fukumoto S, Inoue N, Kawazu S. Improvement of the observational method for Plasmodium berghei oocysts in the midgut.


